Table 1. Summary of statistical analysis of early (P35–P40) or late adolescent (P47–P52) cannabinoid effects on normalized oscillation power in adult neocortex.

(A) In adult mPFC, effects of early or late-adolescent cannabinoid exposure were compared between treatment conditions with KS tests. Percentages reported are the median normalized LFP power in the treatment after “vs” relative to the median normalized LFP power in the treatment before “vs” in the statistical comparison. (B) Same as in (A), but in adult SCx.

A
Adolescent Cannabinoid Treatment	mPFC
Early Adolescent (P35–P40) WIN Treatment Vehicle (n = 11 slices/4 mice) vs. WIN (2 mg/kg) (n = 10 slices/4 mice)	p = 0.017, 52%
Early Adolescent (P35–P40) AM251 Treatment Vehicle (n = 11 slices/4 mice) vs. AM251 (2 mg/kg) (n = 13 slices/5 mice)	p = 0.707
Early Adolescent (P35–P40) AM251 + WIN Treatment WIN (2 mg/kg) (n = 10 slices/4 mice) vs. AM251 (2 mg/kg) + WIN (2 mg/kg) (n = 13 slices/5 mice) Vehicle (n = 11 slices/4 mice) vs. AM251 (2 mg/kg) + WIN (2 mg/kg) (n = 13 slices/5 mice)	p = 0.008, 194% p = 0.278
Late Adolescent (P47–P52) WIN Treatment Vehicle (n = 14 slices/5 mice) vs. WIN (2 mg/kg) (n = 13 slices/5 mice)	p = 0.057
Late Adolescent (P47–P52) AM251 Treatment Vehicle (n = 14 slices/5 mice) vs. AM251 (2 mg/kg) (n = 15 slices/5 mice)	p = 0.137

B
Adolescent Cannabinoid Treatment	SCx
Early Adolescent (P35–P40) WIN Treatment Vehicle (n = 12 slices/4 mice) vs. WIN (2 mg/kg) (n = 11 slices/4 mice)	p = 0.104
Early Adolescent (P35–P40) AM251 Treatment Vehicle (n = 12 slices/4 mice) vs. AM251 (2 mg/kg) (n = 15 slices/5 mice)	p = 0.104
Late Adolescent (P47–P52) WIN Treatment Vehicie (n = 15 slices/5 mice) vs. WIN (2 mg/kg) (n = 15 slices/5 mice)	p = 0.064
Late Adolescent (P47–P52) AM251 Treatment Vehicle (n = 15 slices/5 mice) vs. AM251 (2 mg/kg) (n = 15 slices/5 mice)	p = 0.160